Anti-competitive behaviour in market for hydrocortisone tablets

On the surface this is a classic example of anti-competitive behaviour in a duopolistic market.

The CMA has alleged that Concordia and Actavis signed illegal agreements which enabled high prices for a life-saving drug to be prolonged. Naturally the announcement has brought a wave of criticism for the businesses involved because the cost of higher prices for drugs routinely used in the NHS are ultimately paid for by the taxpayer.

You can read more about the case here on the CMA website